



Attorney's Docket No. G00694.70002.US

1644

6
RECEIVED
OCT 22 2002


TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Richard S. Blumberg
Serial No. : 09/884,196
Filed : June 19, 2001
For : T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES
THEREOF
Examiner : A. DeCloux
Art Unit : 1644
Conf. No. : 5225

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 10th day of October, 2002.


Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

☒ Response to Restriction Requirement

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is required. If a fee is determined to be required, the fee may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By: 
John R. Van Amsterdam, Reg No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. G00694.70002.US
Dated: October 10, 2002
X10/10/02



Attorney's Docket No. G00694.70002.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Richard S. Blumberg
Serial No. : 09/884,196
Filed : June 19, 2001
For : T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES
THEREOF
Examiner : A. DeCloux
Art Unit : 1644
Conf. No. : 5225

TECH CENTER 1600/2900

OCT 22 2002

RECEIVED

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 10th day of October, 2002.


Monica E. Zombori

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is responsive to the restriction requirement mailed on September 10, 2002.
Applicants elect Group I, claims 10-12, 16-18 and 57-58, for prosecution with traverse.

Remarks

Applicants traverse the restriction requirement on the basis that no additional burden would be placed on the Examiner to search and examine the claims in Groups III in addition to those in elected Group I.

The Examiner notes that the methods of Groups I and III are related in that they each require the use of an antibody as the agent that selectively cross-links biliary glycoprotein polypeptides, and that the endpoints of the methods are the same. The Examiner then states that differences between the methods of Groups I and III are that Group I methods are in vivo methods and Group III methods are in vitro methods. Applicants agree that this is the only